35O Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer

ConclusionOur data suggests that the treatment with PD-1 disrupted anti- MUC1-CAR cells is safe and well tolerated by all NSCLC patients. Importantly no CRS was indicated in all cases. The efficacy of this unique combined therapy was still inconclusive and will be explored in our next phase study.Clinical trial identificationNCT03525782.Legal entity responsible for the studyGuangzhou Anjie Biomedical Technology Co. Ltd.FundingGuangzhou Anjie Biomedical Technology Co. Ltd.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research